Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Marco Investment Management LLC

Marco Investment Management LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 12,158 shares of the medical research company’s stock after selling 197 shares during the period. Marco Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $6,453,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Silver Oak Securities Incorporated acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $240,000. Magnus Financial Group LLC increased its stake in shares of Thermo Fisher Scientific by 2.9% in the fourth quarter. Magnus Financial Group LLC now owns 3,076 shares of the medical research company’s stock valued at $1,633,000 after purchasing an additional 88 shares during the period. Little House Capital LLC increased its stake in shares of Thermo Fisher Scientific by 2.8% in the fourth quarter. Little House Capital LLC now owns 4,590 shares of the medical research company’s stock valued at $2,436,000 after purchasing an additional 127 shares during the period. Legacy Capital Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 13.1% in the fourth quarter. Legacy Capital Wealth Partners LLC now owns 1,885 shares of the medical research company’s stock valued at $1,001,000 after purchasing an additional 218 shares during the period. Finally, Paradigm Financial Partners LLC increased its stake in shares of Thermo Fisher Scientific by 1.7% in the fourth quarter. Paradigm Financial Partners LLC now owns 9,688 shares of the medical research company’s stock valued at $5,142,000 after purchasing an additional 158 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Royal Bank of Canada raised their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. The Goldman Sachs Group raised their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Barclays raised their price objective on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $606.76.

Thermo Fisher Scientific Trading Up 0.3 %

Thermo Fisher Scientific stock traded up $1.87 during midday trading on Friday, reaching $573.60. The stock had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. The firm’s fifty day simple moving average is $573.60 and its two-hundred day simple moving average is $530.40. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.39. The firm has a market cap of $218.95 billion, a price-to-earnings ratio of 36.79, a PEG ratio of 2.42 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 5,547 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the transaction, the chief executive officer now owns 43,608 shares in the company, valued at approximately $24,011,436.96. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 in the last quarter. 0.32% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.